In the study, you will be treated with guselkumab, also known as Tremfya, for up to 96 weeks. Study visits will occur every 1-2 months. During the study visits, questionnaires, photographs, throat cultures, and skin samples may be taken.
Prior to the screening visit, we would go through the consent form with you, which fully describes the study along with its benefits and risks. We anticipate the consent and screening visit to take around an hour and the research visits to take about 1-2 hours.